evaluating the interchangeability of hrd testing in ovarian cancer
Published 7 months ago • 89 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
0:52
the importance of hrd testing in ovarian cancer
-
1:19
testing hrd in the clinic
-
1:15
the influence of hrd testing in precision medicine
-
6:28
ovarian cancer: what is the role of hrd testing?
-
59:08
hrd testing in ovarian cancer - what do you need to consider?
-
3:46
illumina oncology - homologous recombination deficiency (hrd) testing in ovarian cancer
-
2:39
testing for brca and hrd in ovarian cancer
-
12:05
the rationale for hrd genomic instability testing in patients with advanced ovarian cancer
-
1:31
ctdna and hrd analysis of a phase ii trial of atezolizumab combo in recurrent ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
3:46
introduction to homologous recombination deficiency (hrd) assessment
-
0:54
identifying optimal patient subgroups in ovarian cancer for neoadjuvant parp inhibitor therapy
-
21:06
genetic testing in early and recurrent ovarian cancer | 2022 evolution conference
-
1:38
updates in parp inhibition for ovarian cancer
-
2:17
hrd in ovarian cancer: defined today, evolving for the future
-
2:05
hrd testing in ovarian cancer
-
1:01
esmo 2023 highlights in the treatment of ovarian cancer
-
3:11
ovarian cancer phase iii trial updates: imagyn050 and icon8